Sudeep Pharma's Q4 FY 2025-26 Quarterly Results

Result Summary

• Sudeep Pharma Ltd reported a 5.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 17.0%.
• Its expenses for the quarter were up by 7.4% QoQ and 21.9% YoY.
• The net profit increased 1.8% QoQ and increased 9.8% YoY.
• The earnings per share (EPS) of Sudeep Pharma Ltd stood at 4.38 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Sudeep Pharma Ltd is a company operating in the pharmaceutical industry. The company's main products or services include a range of pharmaceutical formulations and raw materials. The pharmaceutical industry is characterized by its focus on research and development, regulatory compliance, and a strong emphasis on quality and efficacy of products. Recent developments in the pharmaceutical sector generally include advancements in drug formulations, expansion into emerging markets, and strategic collaborations. However, specific recent developments concerning Sudeep Pharma Ltd are not available from the provided data.

Revenue

In Q4FY26, Sudeep Pharma Ltd reported a total income of ₹188.76 crores. This represents a quarter-over-quarter (QoQ) growth of 5.4% compared to ₹179.17 crores in Q3FY26 and a year-over-year (YoY) increase of 17.0% from ₹161.31 crores in Q4FY25. The consistent increase in revenue suggests positive momentum in the company's sales performance over the past year. The revenue growth could be attributed to a variety of factors, including increased market penetration, product launches, or price adjustments, although specific drivers are not detailed in the available data.

Profitability

Profitability for Sudeep Pharma Ltd in Q4FY26 is reflected by a profit before tax (PBT) of ₹62.69 crores, marking a QoQ growth of 1.5% over ₹61.78 crores in Q3FY26 and a YoY increase of 8.4% from ₹57.85 crores in Q4FY25. The profit after tax (PAT) for this quarter stands at ₹48.54 crores, also showing a QoQ increase of 1.8% from ₹47.70 crores in the previous quarter and a YoY rise of 9.8% compared to ₹44.19 crores in the same quarter of the previous fiscal year. Earnings per share (EPS) reached ₹4.38, exhibiting a QoQ growth of 2.1% and a YoY growth of 7.6%. These metrics indicate that Sudeep Pharma Ltd has maintained a steady improvement in its profitability measures over the past year.

Operating Metrics

The operating performance of Sudeep Pharma Ltd is further illustrated by its expense management and tax obligations. Total expenses for Q4FY26 were reported at ₹126.06 crores, which reflects a 7.4% increase QoQ from ₹117.39 crores in Q3FY26 and a 21.9% increase YoY from ₹103.45 crores in Q4FY25. The tax expenses for Q4FY26 amounted to ₹14.15 crores, showing minimal change with a 0.5% QoQ increase from ₹14.08 crores and a 3.5% YoY increase from ₹13.67 crores. The company's expense growth rate outpacing revenue growth may be attributed to various operational factors, such as increased production costs or strategic investments, but specific details are not outlined in the data provided.